Topical Rapamycin to Erase Angiofibromas in TSC

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
AngiofibromasTuberous Sclerosis
Interventions
DRUG

Placebo

Study cream is applied nightly to the affected areas on the face.

DRUG

Rapamycin

Study cream is applied nightly to the affected areas on the face. Low Dose

DRUG

Rapamycin

Study cream is applied nightly to the affected areas on the face. High Dose

Trial Locations (10)

21205

Kennedy Krieger Institute, Baltimore

35294

University of Alabama at Birmingham, Birmingham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

75219

Texas Scottish Rite Hospital, Dallas

77030

The University of Texas Medical School at Houston, Houston

90095

UCLA Mattel Children's Hospital, Los Angeles

94609

Jack & Julia Center for TSC at Oakland Children's Hospital & Research Center, Oakland

02114

Herscot Center for Adults and Children with TSC Massachusetts General Hospital, Boston

55102-2697

Clinic Without Walls, Saint Paul

Unknown

Sydney Children's Hospital, Sydney

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT01526356 - Topical Rapamycin to Erase Angiofibromas in TSC | Biotech Hunter | Biotech Hunter